8-K

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported): April 12, 2005

Illumina, Inc.
__________________________________________
(Exact name of registrant as specified in its charter)

Delaware	000-30361	330804655
_____________________ (State or other jurisdiction	_____________ (Commission	______________ (I.R.S. Employer
of incorporation)	File Number)	Identification No.)
9885 Towne Centre Drive, San Diego, California		92121
_________________________________ (Address of principal executive offices)		___________ (Zip Code)

Registrant’s telephone number, including area code: 858 202 4500

Not Applicable
______________________________________________
Former name or former address, if changed since last report

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

[  ]  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[  ]  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[  ]  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[  ]  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 5.02. Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers.

On April 12, 2005, Paul Grint, M.D. was appointed to serve as a member of the Board of Directors of Illumina, Inc. ("Illumina"), serving in the class of directors whose term expires at the annual meeting of stockholders in 2007. Dr. Grint will receive a quarterly retainer of $2,500, as well as additional compensation of $2,000 for attendance at each board meeting and $1,000 for attendance at each meeting of a committee of the board. In addition, Dr. Grint received a stock option for 20,000 shares of common stock, vesting annually over a four-year period, pursuant to the terms of the 2000 Stock Plan.

In addition, on April 12, 2005, Illumina announced that R. Scott Greer resigned as a member of the Board of Directors, effective as of such date. Illumina issued a press release on April 12, 2005 related to Dr. Grint's appointment and Mr. Greer's resignation, a copy of which is filed as Exhibit 99.1 hereto.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	Illumina, Inc.
April 15, 2005	By:	Timothy M. Kish
		Name: Timothy M. Kish
		Title: Chief Financial Officer

Exhibit Index

Exhibit No.	Description
99.1	Press release dated April 12, 2005 announcing that Paul Grint, M.D. has joined the Company's Board of Directors and Scott Greer has resigned.

EX-99.1

Exhibit 99.1

ILLUMINA APPOINTS DR. PAUL GRINT TO BOARD OF DIRECTORS

SAN DIEGO, CALIFORNIA, April 12, 2005 — Illumina, Inc. (NASDAQ: ILMN) announced today that Paul Grint, M.D., has joined the Company’s Board of Directors.

Dr. Grint is currently Senior Vice President and Chief Medical Officer of Zephyr Sciences, Inc., a biopharmaceutical company. Prior to joining Zephyr, Grint was Vice President and Head of Clinical Research and Development for Pfizer in La Jolla. He held similar positions at IDEC Pharmaceuticals, Schering-Plough and Wellcome Research Laboratories. Dr. Grint received his medical degree from the University of London, St. Bartholomew’s Hospital Medical College in London, U.K. He is a Fellow of the Royal College of Pathologists, a member of numerous professional and medical societies, and the author or coauthor of over 50 publications.

“We’re very pleased that Paul is joining our Board of Directors,” said Jay Flatley, Illumina President and CEO. “He has extensive experience in the clinical arena, particularly in immunology, infectious diseases and oncology. We look forward to tapping his expertise as we deploy our BeadArray technology platform into clinical research and molecular diagnostics applications.”

Illumina also announced that Scott Greer, Chairman of Abgenics, Inc. and a Board member since May 2001, has resigned from the Board of Directors effective April 12, 2005. “We are deeply indebted to Scott for his numerous contributions to Illumina during his board tenure and we wish him well in his future endeavors,” stated Flatley.

About Illumina
Illumina (www.illumina.com) is developing next-generation tools that permit large-scale analysis of genetic variation and function. The Company’s proprietary BeadArrayÔ technology — now used in leading genome centers around the world — provides the throughput, cost effectiveness and flexibility to enable researchers in the life sciences and pharmaceutical industries to perform the billions of tests necessary to extract medically valuable information from advances in genomics and proteomics. This information will help pave the way to personalized medicine.

“Safe Harbor” Statement under the Private Securities Litigation Reform Act of 1995: this release may contain forward-looking statements that involve risks and uncertainties. Among the important factors that could cause actual results to differ materially from those in any forward-looking statements are the costs and outcome of Illumina’s litigation with Affymetrix, the Company’s ability to scale and integrate CyVera technology, the ability to further scale oligo synthesis output and technology to satisfy market demand deriving from the Company’s collaboration with Invitrogen, Illumina’s ability to further develop and commercialize its Infinium assay and BeadArray platform technologies, to deploy new gene expression and genotyping products and applications for its platform technology, to manufacture robust Sentrix^® arrays and Oligator^® oligonucleotides, and other factors detailed in the Company’s filings with the Securities and Exchange Commission including its recent filings on Forms 10-K and 10-Q or in information disclosed in public conference calls, the date and time of which are released beforehand. Illumina disclaims any intent or obligation to update these forward-looking statements beyond the date of this release.

# # #

Contacts: Jay Flatley
President & CEO
1.858.202.4501
jflatley@illumina.com William Craumer
Director, Corporate Communications
1.858.202.4667
bcraumer@illumina.com